We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Autotaxin (ENPP2)

Autotaxin inhibitors act on the secreted enzyme that produces the lipid mediator lysophosphatidic acid (LPA). Autotaxin, also called ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), is a lysophospholipase D that releases LPA from lysophosphatidylcholine. LPA signals through G protein-coupled receptors to regulate cell proliferation, migration and survival. Autotaxin has therefore been studied in cancer cell motility, fibrosis and inflammation. In mouse models, autotaxin expression in the lung contributes to the development of pulmonary fibrosis. Compounds in this category include PF-8380, HA130, PAT-505 and Autotaxin-IN-1, for studies of the autotaxin-LPA axis.

1 Item

  • BrP-LPA
    Cat. No.
    A42183
    CAS No.
    944313-05-7

    BrP-LPA

    BrP-LPA is a potent lysophosphatidic acid (LPA) antagonist and autotoxin (ATX) inhibitor. It exhibits broad-spectrum antagonism against LPA receptors LPA1-4, resulting in decreased blood vessel density and reduced anxiety-like behaviors. Additionally, BrP-LPA demonstrates significant anticancer activity, effectively inhibiting cell proliferation in breast, colon, and lung cancer models. This compound is valuable for research focused on cancer biology and vasculature modulation.

    View Details

    Out of stock

    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...